Skip to main content
Erschienen in: Journal of Artificial Organs 2/2013

01.06.2013 | Original Article

A potential therapeutic system for Alzheimer’s disease using adsorbents with alkyl ligands for removal of blood amyloid β

verfasst von: Kazunori Kawaguchi, Masato Takeuchi, Hiromasa Yamagawa, Kazutaka Murakami, Sigeru Nakai, Hideo Hori, Atsushi Ohashi, Yoshiyuki Hiki, Nobuo Suzuki, Satoshi Sugiyama, Yukio Yuzawa, Nobuya Kitaguchi

Erschienen in: Journal of Artificial Organs | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Amyloid beta proteins (Aβ) in the brain are the main cause of Alzheimer’s disease. Peripheral administration of Aβ-binding substances, which may act as a sink for Aβ from the brain, has been reported to reduce brain Aβ. We previously found C16-cellulose beads had high Aβ-removal activity in vitro. In this study, we investigated the optimum surface properties of adsorbents for removal of Aβ in vitro and in humans. Batch analysis was performed with porous cellulose beads or silica beads with or without 2–22 methylene groups. Aβ-removal activity of C16-cellulose beads increased with increasing alkyl chain length. In contrast, with cellulose the amount of Aβ removed by the silica beads decreased with increasing alkyl chain length. Cellulose beads with 16 or 22 methylene groups were best (over 99 % removal) among all the beads tested (p ≤ 0.01). The adsorbent surfaces were analyzed by near-infrared spectroscopy, which revealed that the optimum beads had a sufficiently hydrophobic surface with an appropriate amount of adsorbed water accessible on the surface. Aβ removal efficiency by C16-cellulose beads was investigated for 5 renal failure patients on hemodialysis, resulting in 51.1 ± 6.6 % for Aβ1–40 and 43.8 ± 4.5 % for Aβ1–42 (p ≤ 0.01). In conclusion, cellulose beads with 16 or 22 methylene groups and an appropriate amount of adsorbed water were the optimum Aβ adsorbents. The device with C16-cellulose beads had high Aβ removal activity in humans. These adsorbents might be useful for Alzheimer’s disease therapy.
Literatur
1.
Zurück zum Zitat Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–66.PubMed Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–66.PubMed
2.
Zurück zum Zitat Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-β peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950–8.PubMedCrossRef Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-β peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950–8.PubMedCrossRef
3.
Zurück zum Zitat Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.PubMedCrossRef Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.PubMedCrossRef
4.
Zurück zum Zitat Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38:547–54.PubMedCrossRef Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38:547–54.PubMedCrossRef
5.
Zurück zum Zitat Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci. 2003;23:29–33.PubMed Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci. 2003;23:29–33.PubMed
6.
Zurück zum Zitat Liu Y, Studzinski C, Beckett T, Guan H, Murphy MP, Klein R, Hersh LB. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther. 2009;17:1381–6.PubMedCrossRef Liu Y, Studzinski C, Beckett T, Guan H, Murphy MP, Klein R, Hersh LB. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther. 2009;17:1381–6.PubMedCrossRef
7.
Zurück zum Zitat Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, Olazarán J, Roca I, Cuberas G, Tárraga L, Buendia M, Pla RP, Ferrer I, Páez A. Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect. 2009;22:325–39.PubMedCrossRef Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, Olazarán J, Roca I, Cuberas G, Tárraga L, Buendia M, Pla RP, Ferrer I, Páez A. Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect. 2009;22:325–39.PubMedCrossRef
8.
Zurück zum Zitat Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.PubMedCrossRef Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.PubMedCrossRef
9.
Zurück zum Zitat Geylis V, Steinitz M. Immunotherapy of Alzheimer’s disease (AD): from murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev. 2006;5:33–9.PubMedCrossRef Geylis V, Steinitz M. Immunotherapy of Alzheimer’s disease (AD): from murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev. 2006;5:33–9.PubMedCrossRef
10.
Zurück zum Zitat Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64:94–101.PubMedCrossRef Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64:94–101.PubMedCrossRef
11.
Zurück zum Zitat DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-b efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science. 2002;295:2264–7.PubMedCrossRef DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-b efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science. 2002;295:2264–7.PubMedCrossRef
12.
Zurück zum Zitat Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405–15.PubMedCrossRef Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405–15.PubMedCrossRef
13.
Zurück zum Zitat Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18.PubMed Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18.PubMed
14.
Zurück zum Zitat Kawaguchi K, Kitaguchi N, Nakai S, Murakami K, Asakura K, Mutoh T, Fujita Y, Sugiyama S. Novel therapeutic approach for Alzheimer’s disease by removing amyloid-β protein from the brain with an extracorporeal removal system. J Artif Organs. 2010;13:31–7.PubMedCrossRef Kawaguchi K, Kitaguchi N, Nakai S, Murakami K, Asakura K, Mutoh T, Fujita Y, Sugiyama S. Novel therapeutic approach for Alzheimer’s disease by removing amyloid-β protein from the brain with an extracorporeal removal system. J Artif Organs. 2010;13:31–7.PubMedCrossRef
15.
Zurück zum Zitat Kitaguchi N, Kawaguchi K, Nakai S, Murakami K, Ito S, Hoshino H, Hori H, Ohashi A, Shimano Y, Suzuki N, Yuzawa Y, Mutoh T, Sugiyama S. Reduction of Alzheimer’s disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions. Blood Purif. 2011;32:57–62.PubMedCrossRef Kitaguchi N, Kawaguchi K, Nakai S, Murakami K, Ito S, Hoshino H, Hori H, Ohashi A, Shimano Y, Suzuki N, Yuzawa Y, Mutoh T, Sugiyama S. Reduction of Alzheimer’s disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions. Blood Purif. 2011;32:57–62.PubMedCrossRef
16.
Zurück zum Zitat Kato M, Kawaguchi K, Nakai S, Murakami K, Hori H, Ohashi A, Hiki Y, Ito S, Shimano Y, Suzuki N, Sugiyama S, Ogawa H, Kusimoto H, Mutoh T, Yuzawa Y, Kitaguchi N. Potential therapeutic system for Alzheimer’s disease: removal of blood Abs by hemodialyzers and its effect on the cognitive functions of renal-failure patients. J Neural Transm. doi 10.1007/s00702-012-0844-5 (in press). Kato M, Kawaguchi K, Nakai S, Murakami K, Hori H, Ohashi A, Hiki Y, Ito S, Shimano Y, Suzuki N, Sugiyama S, Ogawa H, Kusimoto H, Mutoh T, Yuzawa Y, Kitaguchi N. Potential therapeutic system for Alzheimer’s disease: removal of blood Abs by hemodialyzers and its effect on the cognitive functions of renal-failure patients. J Neural Transm. doi 10.​1007/​s00702-012-0844-5 (in press).
17.
Zurück zum Zitat Chalmers JM, Griffiths PR. Handbook of vibrational spectroscopy, vol. 3. Wiley: New York; 2002. Chalmers JM, Griffiths PR. Handbook of vibrational spectroscopy, vol. 3. Wiley: New York; 2002.
18.
Zurück zum Zitat Takeuchi M, Bertinetti L, Martra G, Coluccia S, Anpo M. States of H2O adsorbed on oxides: an investigation by near and mid infrared spectroscopy. Appl Catal A-Gen. 2006;307:13–20.CrossRef Takeuchi M, Bertinetti L, Martra G, Coluccia S, Anpo M. States of H2O adsorbed on oxides: an investigation by near and mid infrared spectroscopy. Appl Catal A-Gen. 2006;307:13–20.CrossRef
19.
Zurück zum Zitat Takeuchi M, Martra G, Coluccia S, Anpo M. Evaluation of the adsorption states of H2O on oxide surfaces by vibrational absorption: near- and mid-infrared spectroscopy. J Near Infrared Spectrosc. 2009;17:373–84.CrossRef Takeuchi M, Martra G, Coluccia S, Anpo M. Evaluation of the adsorption states of H2O on oxide surfaces by vibrational absorption: near- and mid-infrared spectroscopy. J Near Infrared Spectrosc. 2009;17:373–84.CrossRef
20.
Zurück zum Zitat Klier K, Shen JH, Zettlemoyer AC. Water on silica and silicate surfaces. I. Partially hydrophobic silicas. J Phys Chem. 1973;77:1458–65.CrossRef Klier K, Shen JH, Zettlemoyer AC. Water on silica and silicate surfaces. I. Partially hydrophobic silicas. J Phys Chem. 1973;77:1458–65.CrossRef
21.
Zurück zum Zitat Morrow BA, Cody IA. Infrared spectra of the isolated hydroxyl groups on silica. J Phys Chem. 1973;77:1465–9.CrossRef Morrow BA, Cody IA. Infrared spectra of the isolated hydroxyl groups on silica. J Phys Chem. 1973;77:1465–9.CrossRef
Metadaten
Titel
A potential therapeutic system for Alzheimer’s disease using adsorbents with alkyl ligands for removal of blood amyloid β
verfasst von
Kazunori Kawaguchi
Masato Takeuchi
Hiromasa Yamagawa
Kazutaka Murakami
Sigeru Nakai
Hideo Hori
Atsushi Ohashi
Yoshiyuki Hiki
Nobuo Suzuki
Satoshi Sugiyama
Yukio Yuzawa
Nobuya Kitaguchi
Publikationsdatum
01.06.2013
Verlag
Springer Japan
Erschienen in
Journal of Artificial Organs / Ausgabe 2/2013
Print ISSN: 1434-7229
Elektronische ISSN: 1619-0904
DOI
https://doi.org/10.1007/s10047-012-0675-z

Weitere Artikel der Ausgabe 2/2013

Journal of Artificial Organs 2/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.